Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice.
about
Probiotics in prevention and treatment of obesity: a critical viewProbiotics as Complementary Treatment for Metabolic DisordersSaccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis - a reviewInfluence of Saccharomyces boulardii CNCM I-745on the gut-associated immune systemMetabolic Engineering of Probiotic Saccharomyces boulardiiAmerican Diabetes Association and JDRF Research Symposium: Diabetes and the MicrobiomeThe Gut Microbiota: The Gateway to Improved Metabolism.Entamoeba bangladeshi: An insight.Antioxidant Properties of Probiotic Bacteria.Obesity and microbiota: an example of an intricate relationship.Human gut Bacteroidetes can utilize yeast mannan through a selfish mechanismThe dormant blood microbiome in chronic, inflammatory diseases.Oral administration of Saccharomyces boulardii ameliorates carbon tetrachloride-induced liver fibrosis in rats via reducing intestinal permeability and modulating gut microbial composition.Gut microbial markers are associated with diabetes onset, regulatory imbalance, and IFN-γ level in NOD mice.Influence of high-fat diet on gut microbiota: a driving force for chronic disease risk.Gut microorganisms as promising targets for the management of type 2 diabetes.Effect of dietary supplementation of Bacillus subtilis B10 on biochemical and molecular parameters in the serum and liver of high-fat diet-induced obese mice.Akkermansia muciniphila inversely correlates with the onset of inflammation, altered adipose tissue metabolism and metabolic disorders during obesity in miceThe efficacy and safety of probiotics intervention in preventing conversion of impaired glucose tolerance to diabetes: study protocol for a randomized, double-blinded, placebo controlled trial of the Probiotics Prevention Diabetes Programme (PPDP).Cellular and molecular effects of yeast probiotics on cancer.Kluyveromyces marxianus and Saccharomyces boulardii Induce Distinct Levels of Dendritic Cell Cytokine Secretion and Significantly Different T Cell Responses In Vitro.Infant fungal communities: current knowledge and research opportunities.Potential mechanisms linking probiotics to diabetes: a narrative review of the literature.Nutritional modulation of gut microbiota - the impact on metabolic disease pathophysiologyCharacterization of the Probiotic Yeast Saccharomyces boulardii in the Healthy Mucosal Immune System.Mechanisms of body weight reduction and metabolic syndrome alleviation by tea.Dynamic In Vitro Models of the Human Gastrointestinal Tract as Relevant Tools to Assess the Survival of Probiotic Strains and Their Interactions with Gut Microbiota.The Gut Microbiome and Its Role in Obesity.Prospective randomized controlled study on the effects of Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate or the combination on the gut microbiota of healthy volunteers.Probiotics as beneficial agents in the management of diabetes mellitus: a systematic review.Probiotics and Disease: A Comprehensive Summary-Part 3, Cardiometabolic Disease and Fatigue Syndromes.Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies.Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet.Biotechnological application of yeasts in food science: Starter cultures, probiotics and enzyme production.Saccharomyces boulardii Administration Changes Gut Microbiota and Attenuates D-Galactosamine-Induced Liver Injury.Ecological Therapeutic Opportunities for Oral Diseases.High-Fat Diet Changes Fungal Microbiomes and Interkingdom Relationships in the Murine Gut.Gut microbiome in gestational diabetes: A Cross-sectional study of mothers and offspring 5 years post-partum.Microbial Mechanistic Insight into the Role of Inulin in Improving Maternal Health in a Pregnant Sow Model.Dual function of Lactobacillus kefiri DH5 in preventing high-fat-diet-induced obesity: direct reduction of cholesterol and upregulation of PPAR-α in adipose tissue.
P2860
Q26768518-1CC91440-AE2C-4844-8617-93BBC6AD364EQ26795371-A9E8E54E-D913-41BB-8FF5-E02D72DECBD0Q26796416-87F704B7-2D38-4301-BE53-FA1D3A9D1218Q28066899-9C08469D-599A-497A-962F-A19817EB250FQ28272961-F38310CA-4D65-4D62-BA4A-422BBACBC05AQ28602363-72A0026A-8206-4078-A0C7-051B070C4A85Q30241392-15D030F2-0C06-43C7-9606-EB2215B3291BQ30410608-8F826B20-E865-47D7-849E-82B2147D9389Q33749630-E16F58C4-7C09-4EF6-9F16-5AB745078980Q33805550-474AFAB7-6A50-4676-AF04-AF42D48D4651Q34457059-BEC084F5-76E0-4DFF-98D5-871486FE154EQ34474989-2A3B4253-8105-4B22-AD24-84108B0584B2Q35256601-5F05CE69-1582-43FC-8735-FBF0B36D7A6CQ35554609-C13CC2D8-F329-4FBF-BC4A-9C11E70392EFQ35685937-D60ED28C-5D00-4BC4-858C-273C017ED9D2Q35725065-1C4B05E8-7374-40F3-82D9-A45C59C8E5A9Q35753767-2637ED04-3B2D-4FA7-94EC-931B5720E2F6Q35840309-2AA3377C-7717-4A51-B3CE-4700D19367F5Q35857634-0E1DF71B-41D3-4A49-B385-8B3B3352C0EFQ36113199-2F9E41FC-D134-4CC9-BA3A-4D179E51329EQ36206938-84988D80-A759-472B-87B6-7958B980770FQ36278070-6135FC88-62DB-4F0E-A2DE-4453868C2C67Q36379322-54080A70-5A62-4519-9359-DDFCF16D1434Q36590565-537C88A0-54C1-4C7A-9C1C-9E9BB48BED83Q36787641-4797A6D1-D697-4219-AFFA-9708FD3E05CAQ37191157-56D0DDD0-0C9F-41F2-87C8-0D666DA86690Q37255990-54A27D0A-BBC4-4F76-B2B5-E0320615AFEAQ37371393-B3F0B6F0-E7ED-46C1-BEB3-71E16FFF8729Q37687229-34591692-D7B5-4416-9279-15864397101DQ38473701-C466852E-486E-42B0-99AB-D2088584B01BQ38754711-E438D9D5-45FA-407C-BD91-15E43FC3568AQ38794312-C9F2958D-677A-4F33-988A-F90B149002F2Q39180593-D5BB6175-A65A-4B68-BA16-D81406EBDF4EQ39458900-DE37BC14-4945-4B1D-A500-2D1061490E4FQ40229016-7C426E33-79D1-4AA5-97E6-F7CC0C874288Q41532506-779C4A6B-9C3A-4A3D-8D91-1B2A6B9EC16DQ42374719-61B5E02E-E15E-496D-9CA2-93C08C309945Q46273263-F547D080-56E5-47ED-B804-83BBDAB13151Q47132983-8243F3E4-4AD3-42EF-982A-D11D0CEC9611Q51193316-53DFE688-B6BD-49C5-AD0F-4DEADA0CC2BC
P2860
Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Saccharomyces boulardii admini ...... nd type 2 diabetic db/db mice.
@ast
Saccharomyces boulardii admini ...... nd type 2 diabetic db/db mice.
@en
type
label
Saccharomyces boulardii admini ...... nd type 2 diabetic db/db mice.
@ast
Saccharomyces boulardii admini ...... nd type 2 diabetic db/db mice.
@en
prefLabel
Saccharomyces boulardii admini ...... nd type 2 diabetic db/db mice.
@ast
Saccharomyces boulardii admini ...... nd type 2 diabetic db/db mice.
@en
P2093
P2860
P356
P1433
P1476
Saccharomyces boulardii admini ...... nd type 2 diabetic db/db mice.
@en
P2093
Amandine Everard
Lucie Geurts
Sébastien Matamoros
P2860
P304
P356
10.1128/MBIO.01011-14
P577
2014-06-10T00:00:00Z